Document Type : Original Article(s)
Author
Department of Anatomy, Biology, and Histology, College of Medicine, University of Duhok, Duhok, Iraq
Abstract
Background: Metastases, not the primary tumor, account for most cancer-related deaths. Tumor budding, thought to represent epithelial-mesenchymal transition (EMT), has garnered attention due to its association with invasion and migration. This study aims to assess the pathological and clinical significance of tumor budding in colorectal carcinoma and its correlation with epithelial-mesenchymal transition.
Methods: In this retrospective observational study, tissue samples from 101 patients (no neoadjuvant treatment) were analyzed. Tumor budding was scored using International Tumor Budding Consensus Conference guidelines and classified into Budding 1 (BD1) (1-4 buds), Budding 2 (BD2) (5-9 buds), and Budding 3 (BD3) (10+ buds) per 0.785 mm². The tissue sample was subjected to immunohistochemistry to assess EMT markers: β-catenin, E-cadherin, Snail, and Zinc finger E-box-binding homeobox 1 (ZEB1).
Results: Tumor budding was significantly associated with advanced tumor stage (P=0.0001), deeper invasion (P=0.003), vascular invasion (P=0.001), perineural invasion (P=0.0001), and desmoplasia (P=0.010). Regional lymph node metastasis was seen in 93% of cases with tumor budding, and distant metastasis was found in eight cases (7.9%). Aberrant β-catenin expression was seen in 82 cases (81.2%), and aberrant E-cadherin in 65 cases (64.4%). Snail and ZEB1 positivity were observed in 55 (54.5%) and 32 (31.7%) cases, respectively. A significant correlation was found between aberrant β-catenin and ZEB1 (P=0.005). Although EMT markers coexisted frequently with tumor budding, no statistically significant association was observed.
Conclusion: The results of our study indicate that tumor budding is common in colorectal carcinoma and is significantly associated with advanced tumor stage, invasion, vascular and perineural invasion, and regional lymph node metastasis. Aberrant expression of EMT markers (β-catenin, E-cadherin, Snail, and ZEB1) was frequently observed, although no significant association with tumor budding was found.
Highlights
Bashar Al Hassawi (Google Scholar)
Keywords
- Marmol I, Sanchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int J Mol Sci. 2017;18. doi: 10.3390/ijms18010197. PubMed PMID: 28106826; PubMed Central PMCID: PMCPMC5297828.
- Peng H, Ying J, Zang J, Lu H, Zhao X, Yang P, et al. Specific Mutations in APC, with Prognostic Implications in Metastatic Colorectal Cancer. Cancer Res Treat. 2023;55:1270-80. doi: 10.4143/crt.2023.415. PubMed PMID: 37114476; PubMed Central PMCID: PMCPMC10582542.
- Feldman M, Hershkovitz I, Sklan EH, Kahila Bar-Gal G, Pap I, Szikossy I, et al. Detection of a Tumor Suppressor Gene Variant Predisposing to Colorectal Cancer in an 18th Century Hungarian Mummy. PLoS One. 2016;11:e0147217. doi: 10.1371/journal.pone.0147217. PubMed PMID: 26863316; PubMed Central PMCID: PMCPMC4749341.
- Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev. 2021;35:787-820. doi: 10.1101/gad.348226.120. PubMed PMID: 34074695; PubMed Central PMCID: PMCPMC8168558.
- Satorres C, Garcia-Campos M, Bustamante-Balen M. Molecular Features of the Serrated Pathway to Colorectal Cancer: Current Knowledge and Future Directions. Gut Liver. 2021;15:31-43. doi: 10.5009/gnl19402. PubMed PMID: 32340435; PubMed Central PMCID: PMCPMC7817929.
- Gavert N, Ben-Ze’ev A. Coordinating changes in cell adhesion and phenotype during EMT-like processes in cancer. Biol Rep. 2010;2:86. doi: 10.3410/B2-86. PubMed PMID: 21283595; PubMed Central PMCID: PMCPMC3026620.
- van Wyk HC, Roseweir A, Alexander P, Park JH, Horgan PG, McMillan DC, et al. The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer. Ann Surg Oncol. 2019;26:4397-404. doi: 10.1245/s10434-019-07931-6. PubMed PMID: 31605345; PubMed Central PMCID: PMCPMC6863941.
- Graham RP, Vierkant RA, Tillmans LS, Wang AH, Laird PW, Weisenberger DJ, et al. Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort. Am J Surg Pathol. 2015;39:1340-6. doi: 10.1097/PAS.0000000000000504. PubMed PMID: 26200097; PubMed Central PMCID: PMCPMC4567920.
- Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 2010;1:651-61. doi: 10.18632/oncotarget.199. PubMed PMID: 21317460; PubMed Central PMCID: PMCPMC3248128.
- Haddad TS, Lugli A, Aherne S, Barresi V, Terris B, Bokhorst JM, et al. Improving tumor budding reporting in colorectal cancer: a Delphi consensus study. Virchows Arch. 2021;479:459-69. doi: 10.1007/s00428-021-03059-9. PubMed PMID: 33650042; PubMed Central PMCID: PMCPMC8448718.
- Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30:1299-311. doi: 10.1038/modpathol.2017.46. PubMed PMID: 28548122.
- Lv JH, Wang F, Shen MH, Wang X, Zhou XJ. SATB1 expression is correlated with beta-catenin associated epithelial-mesenchymal transition in colorectal cancer. Cancer Biol Ther. 2016;17:254-61. doi: 10.1080/15384047.2016.1139239. PubMed PMID: 26810818; PubMed Central PMCID: PMCPMC4847995.
- Bruun J, Eide PW, Bergsland CH, Bruck O, Svindland A, Arjama M, et al. E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models. Mol Oncol. 2022;16:2312-29. doi: 10.1002/1878-0261.13159. PubMed PMID: 34890102; PubMed Central PMCID: PMCPMC9208074.
- Sonnenschein C, Soto AM. Cancer Metastases: So Close and So Far. J Natl Cancer Inst. 2015;107. doi: 10.1093/jnci/djv236. PubMed PMID: 26283653; PubMed Central PMCID: PMCPMC4643632.
- Zlobec I, Bachli M, Galuppini F, Berger MD, Dawson HE, Nagtegaal ID, et al. Refining the ITBCC tumor budding scoring system with a “zero-budding” category in colorectal cancer. Virchows Arch. 2021;479:1085-90. doi: 10.1007/s00428-021-03090-w. PubMed PMID: 33843013; PubMed Central PMCID: PMCPMC8724067.
- Pyo JS, Choi JE, Kim NY, Min KW, Kang DW. Comparison between Peritumoral and Intratumoral Budding in Colorectal Cancer. Biomedicines. 2024;12. doi: 10.3390/biomedicines12010212. PubMed PMID: 38255317; PubMed Central PMCID: PMCPMC10813595.
- Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 2012;25:1315-25. doi: 10.1038/modpathol.2012.94. PubMed PMID: 22790014.
- Kang G, Pyo JS, Kim NY, Kang DW. Clinicopathological Significances and Prognostic Role of Intratumoral Budding in Colorectal Cancers. J Clin Med. 2022;11. doi: 10.3390/jcm11195540. PubMed PMID: 36233405; PubMed Central PMCID: PMCPMC9570640.
- Pyo JS, Choi JE, Kim NY, Min KW, Kang DW. Prognostic Implications of Intratumoral Budding in Colorectal Cancer: Detailed Analysis Based on Tumor-Infiltrating Lymphocytes. J Clin Med. 2023;13. doi: 10.3390/jcm13010134. PubMed PMID: 38202141; PubMed Central PMCID: PMCPMC10779795.
- Zlobec I, Hadrich M, Dawson H, Koelzer VH, Borner M, Mallaev M, et al. Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients. Br J Cancer. 2014;110:1008-13. doi: 10.1038/bjc.2013.797. PubMed PMID: 24366305; PubMed Central PMCID: PMCPMC3929877.
- Hussein ZH, Al Hassawi B, Ibraheem Q, Hussein Z, Ismaeel Sr QIA. Aberrant β-catenin expression and its association with epithelial-mesenchymal transition and clinical outcomes of colorectal cancer. Cureus. 2024;16. doi: 10.7759/cureus.53104.
- Bian J, Dannappel M, Wan C, Firestein R. Transcriptional Regulation of Wnt/beta-Catenin Pathway in Colorectal Cancer. Cells. 2020;9. doi: 10.3390/cells9092125. PubMed PMID: 32961708; PubMed Central PMCID: PMCPMC7564852.
- Tamura S, Isobe T, Ariyama H, Nakano M, Kikushige Y, Takaishi S, et al. Ecadherin regulates proliferation of colorectal cancer stem cells through NANOG. Oncol Rep. 2018;40:693-703. doi: 10.3892/or.2018.6464. PubMed PMID: 29845283; PubMed Central PMCID: PMCPMC6072297.
- Gao ZH, Lu C, Wang MX, Han Y, Guo LJ. Differential beta-catenin expression levels are associated with morphological features and prognosis of colorectal cancer. Oncol Lett. 2014;8:2069-76. doi: 10.3892/ol.2014.2433. PubMed PMID: 25295092; PubMed Central PMCID: PMCPMC4186582.
- Hussein ZH, Hassawi BA, Ibraheem Q. Aberrant beta-Catenin Expression and Its Association With Epithelial-Mesenchymal Transition and Clinical Outcomes of Colorectal Cancer. Cureus. 2024;16:e53104. doi: 10.7759/cureus.53104. PubMed PMID: 38414697; PubMed Central PMCID: PMCPMC10897760.
- Bruun J, Kolberg M, Nesland JM, Svindland A, Nesbakken A, Lothe RA. Prognostic Significance of beta-Catenin, E-Cadherin, and SOX9 in Colorectal Cancer: Results from a Large Population-Representative Series. Front Oncol. 2014;4:118. doi: 10.3389/fonc.2014.00118. PubMed PMID: 24904831; PubMed Central PMCID: PMCPMC4033250.
- Katsuno Y, Derynck R. Epithelial plasticity, epithelial-mesenchymal transition, and the TGF-beta family. Dev Cell. 2021;56:726-46. doi: 10.1016/j.devcel.2021.02.028. PubMed PMID: 33756119.
- Pearson GW. Control of Invasion by Epithelial-to-Mesenchymal Transition Programs during Metastasis. J Clin Med. 2019;8. doi: 10.3390/jcm8050646. PubMed PMID: 31083398; PubMed Central PMCID: PMCPMC6572027.
)